Moreno-Arribas, JoséBertomeu-González, VicenteAnguita-Sanchez, ManuelCequier, ÁngelMuñiz, JavierCastillo, JesúsSanchis, JuanRoldán, InmaculadaMarín, FranciscoBertomeu-Martínez, Vicenteinvestigators of the FANTASIIA study2023-01-252023-01-252015-07-30http://hdl.handle.net/10668/10027Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Mean age was 73.8 ± 9.4 years, and 42.5% of the patients were women. The CHA2DS2-VASc score was 0 in 4.9% of the population, 1 in 24.1%, and ≥2 in 71% (median = 4, interquartile range = 2). Variables associated with NOAC treatment were major bleeding (odds ratio [OR] = 3.36; confidence interval [CI] 95%: 1.73-6.51; P Medical and social variables were associated with prescription of NOAC. Major bleeding, hemorrhagic stroke, university education, and higher glomerular filtration rate were more frequent among patients under NOAC. On the contrary, patients with history of cancer or bradyarrhythmias more frequently received VKA.enanticoagulant treatmentatrial fibrillationnonvitamin K antagonist oral anticoagulantsvitamin K antagonistsAdministration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationClinical Decision-MakingFemaleFibrinolytic AgentsHemorrhageHumansMaleMiddle AgedVitamin Kresearch article26229096open access10.1177/10742484155964261940-4034https://ruc.udc.es/dspace/bitstream/2183/16349/2/MorenoArribas_ChoiceNew.pdf